Meet Our New Board Members: Diana Bernstein

Published

August 3, 2022

Meet Our New Board Members: Diana Bernstein

In this new series, we are introducing the new additions to the OMass Board of Directors following our latest round of financing. The aim is to learn a bit more about our new board members and why they were excited to join OMass’s journey.

Diana is currently a Vice President at Northpond Ventures. Previously, Diana was a senior associate at MRL Ventures fund, the corporate venture fund of Merck & Co, investing in early-stage human therapeutics companies. Prior to that, she was an Associate at Flagship Pioneering, leading projects to conceive and build platform-based therapeutics companies.

What attracted you to OMass initially?

I was initially attracted to OMass by the specialized native mass spec approach to solve a major unmet need in drug discovery – simultaneously testing both drug function and drug binding in a single experiment. I was also very impressed with how OMass has demonstrated the utility of this technique in exciting targets that have historically been challenging to drug.

What makes OMass unique?

OMass is a unique group of technology-enabled problem solvers. When I visited the company recently, I was amazed going into the lab and seeing all the instruments that have been customized to answer different scientific questions. To me, this speaks to a culture of curiosity, creativity, and unlimited boundaries.

What excites you most about the company over the next couple of years?

Over the next couple of years, I’m tremendously excited to see all the exciting technology OMass has built translate into a drug that will be ready to test in patients!

Tell us a fun fact about yourself.

This summer I visited the Amalfi Coast and Sardinia and it was the best trip I’ve ever been on! See photo of me in Amalfi, and happy to share recommendations.

 

MORERelated News
On Rare Diseases: In Conversation with Dr Birgitte Volck, Non-Executive Board Director, OMass Therapeutics
Our new non-executive board member Birgitte Volck MD, PhD has decades of experience at companies developing new therapies to treat...
Remembering Prof. Graham Richards, Founding Chair of OMass Therapeutics
It is with heavy hearts that we remember our dear friend Prof. Graham Richards, a colleague, mentor and the first...
Looking Back on 2024: A Year of Progress at OMass Therapeutics
As 2024 draws to a close, it’s great to reflect on the progress we’ve made at OMass. It’s been a...